{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT00517049: Phase 2 Interventional Completed Non-Hodgkin's Lymphoma
(2008)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01786096: Phase 1 Interventional Completed Burkitt Lymphoma
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT04052997: Phase 2 Interventional Completed Relapsed Hodgkin Lymphoma
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:litifilimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00004084: Phase 1/Phase 2 Interventional Completed Leukemia
(1998)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT01574716: Phase 2 Interventional Completed Metastatic Soft Tissue Sarcoma
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02841267: Phase 1/Phase 2 Interventional Completed LGMD2I
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00936403: Phase 2 Interventional Completed Growth Hormone Disorder
(2009)
Source URL:
Class:
PROTEIN
